Ra Capital Management, L.P. Dyne Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $61.3 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$256 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$250 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$172 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$145 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$136 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.65B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...